Dr Reddy’s Laboratories is currently trading at Rs. 1661.00, up by 3.60 points or 0.22% from its previous closing of Rs. 1657.40 on the BSE.
The scrip opened at Rs. 1662.00 and has touched a high and low of Rs. 1665.00 and Rs. 1650.00 respectively.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1818.00 on 20-Apr-2012 and a 52 week low of Rs. 1387.00 on 22-Aug-2011.
Last one week high and low of the scrip stood at Rs. 1680.00 and Rs. 1604.00 respectively. The current market cap of the company is Rs. 28,181.00 crore.
The promoters holding in the company stood at 25.57% while Institutions and Non-Institutions held 40.32% and 17.32% respectively.
Dr Reddy’s Laboratories has launched Montelukast Sodium Tablets (10 mg) and Montelukast Sodium Chewable Tablets (4 mg & 5 mg), bioequivalent generic versions of SINGULAIR tablets and Chewable tablets, in the US market on August 06, 2012 following the approval by the United States Food & Drug Administration (USFDA) of company’s ANDA . The company’s Montelukast Sodium Tablets in 10 mg and Montelukast Sodium Chewable Tablets in 4 mg and 5 mg are available in bottle counts of 30 and 90. The SINGULAIR tablets and Chewable tablets brand had US sales of approximately $3.6 billion and $1.14 billion, respectively for the most recent twelve months ending March 2012 according to IMS Health.
Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1814.50 |
Dr. Reddys Lab | 1340.80 |
Cipla | 1476.45 |
Lupin | 2160.20 |
Zydus Lifesciences | 972.95 |
View more.. |